Previous 10 | Next 10 |
AVEO Pharmaceuticals ( AVEO -45.8% ) slumps out of the gate this morning following its announcement that it will not file a U.S. marketing application seeking approval for FOTIVDA (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma (kidney cancer) until it ...
AVEO Pharmaceuticals (NASDAQ: AVEO ) -41% . More news on: AVEO Pharmaceuticals, Inc., Co-Diagnostics, Resolute Forest Products, Inc., Stocks on the move, , Read more ...
AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS) results from the Phase 3 TIVO-3 trial. The F...
NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Realty Income Corporation (NYSE:O), United Therapeutics Corporation (N...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time. A live webcast of the presentation can be ac...
AVEO Oncology (NASDAQ: AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASC...
CORAL GABLES, FL/ ACCESSWIRE / December 26,2018 / The pharmaceutical industry , like other healthcare related fields, is predicated on the idea that we can do better, in terms of quality of treatment made available to consumers as well as medical technologies created to deliver said treat...
Buy The Decline Novavax ( NVAX ) is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company recently reported quarter 3 earnings earlier this month missing on revenue by $1.89 ...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New Yor...
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Johnson & Johnson Acquires Rights To A Drug That Treats Rare Forms Of Cancer News: Recently, Johnson & Johnson ( JNJ ) announced that it had ...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...